Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LUND, Sweden, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Laquinimod In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod's potential for treatment...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod· I april meddelades att första...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod· In April, it was announced that...
-
LUND, Sweden, Jan. 11, 2016 (GLOBE NEWSWIRE) -- This is a correction of the announcement from 08:30 11.01.2016 CET. Reason for the correction: Swedish version only that is correctedLund, January 11,...
-
LUND, Sweden, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Active Biotech (Nasdaq Stockholm: ACTI) today announces that its partner Teva Pharmaceutical Industries Ltd, will amend the trial design in a Phase 2...
-
Lund den 11 januari 2016 - Active Biotech (Nasdaq Stockholm: ACTI) meddelar idag att dess samarbetspartner Teva Pharmaceutical Industries Ltd kommer att ändra studiedesignen för en fas 2-studie...
-
Lund, January 11, 2016 - Active Biotech (Nasdaq Stockholm: ACTI) today announces that its partner Teva Pharmaceutical Industries Ltd, will amend the trial design in a Phase 2 study of laquinimod...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund den 11 januari 2016 -Active Biotech...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, January 11, 2016 - Active Biotech (Nasdaq...
-
Studierna CONCERTO och ARPEGGIO fortlöper med den lägre dosen laquinimod Jerusalem & Lund, Sverige - 4 januari, 2016 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) och Active...